Ziuzio S, Sakson B
Klinicznego Oddziału Otolaryngologicznego Wojskowego Szpitala Klinicznego w Bydgoszczy.
Wiad Lek. 1994 Jul;47(13-14):510-3.
An analysis was performed of the course of nasal and sinus bacterial allergy in 160 children treated in the years 1981-1990 with bacterial vaccines. History data, results of medical examinations and laboratory investigations, indications and contraindications to vaccine therapy, and the methods and results of treatment are presented. Vaccines available in Poland were used--Polyvaccium (nasal and subcutaneous) produced by Biomed, Broncho-Vaxom, IRS-19. As the main criterion of positive results, improvement or regression of clinical manifestations, normalization of immunoglobulin level, and also extinction of organ reactions and generalized and local skin reactions to bacterial allergens, were accepted. Very good and good results were achieved in 63% of the studied patients. The best results were achieved using combined treatment--vaccine therapy, anti-inflammatory drugs, and symptomatic antiallergic treatment (68% of positive results). In comparison to the control group (80 children) in which no vaccine therapy was used, the results obtained in the studied group were statistically significantly better.
对1981年至1990年间接受细菌疫苗治疗的160名儿童的鼻和鼻窦细菌性过敏病程进行了分析。文中呈现了病史数据、医学检查和实验室调查结果、疫苗治疗的适应证和禁忌证，以及治疗方法和结果。使用了波兰现有的疫苗——由Biomed生产的Polyvaccium（鼻用和皮下注射）、Broncho-Vaxom、IRS-19。作为阳性结果的主要标准，接受了临床表现的改善或消退、免疫球蛋白水平的正常化，以及对细菌过敏原的器官反应和全身性及局部皮肤反应的消失。63%的研究患者取得了非常好和良好的结果。联合治疗——疫苗治疗、抗炎药物和对症抗过敏治疗取得了最佳效果（阳性结果占68%）。与未使用疫苗治疗的对照组（80名儿童）相比，研究组获得的结果在统计学上有显著改善。
